Moderna (MRNA) News Today

Moderna logo
$207.19 +7.86 (+3.94%)
As of 10:04 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Why Is Moderna Up Today?

Moderna, Inc. (NASDAQ: MRNA) is facing pressure as investors balance encouraging cancer-vaccine results against rising costs and uncertainty about growth beyond its COVID-19 vaccine business. Recent coverage describes a sharp weekly decline, with shares also falling below their 50-day moving average.

  • Positive Sentiment: Moderna’s Phase 3 melanoma-vaccine study with Merck’s Keytruda showed a lower risk of recurrence or death, bolstering the long-term potential of its oncology pipeline. Article: Moderna's Cancer Vaccine Worked
  • Positive Sentiment: A separate report says Morgan Stanley sees potential for substantial share-price appreciation, offering a counterpoint to recent weakness. Article: Morgan Stanley Forecasts Strong Price Appreciation
  • Neutral Sentiment: President Stephen Hoge sold shares in transactions reported as being made under a pre-arranged Rule 10b5-1 plan. The sales may concern investors, but the plan-based transactions alone do not necessarily signal a change in his view of the company. Article: Moderna President Sells Stock
  • Negative Sentiment: Investors are weighing reports that Moderna’s cash costs could reach $4 billion in 2027. The spending burden, alongside uncertainty over future vaccine revenue and whether the business can fund its next growth phase, is a key concern. Article: Moderna's 2027 Cash Costs
  • Negative Sentiment: Investor Bireme Capital disclosed that it sold its Moderna position after the stock’s rally, adding to concerns about whether recent gains can be sustained. Article: Bireme Capital Sold Moderna
Posted 35m agoAI Generated. May Contain Errors.

Moderna Latest News

Moderna (NASDAQ:MRNA) Stock: Insider Stephen Hoge Sells 39,160 Shares
Bireme Capital Sold Moderna (MRNA) Following Record Rally
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth?
Bireme Capital Sold Moderna (MRNA) Following Record Rally
Moderna (NASDAQ:MRNA) President Sells $8,298,286.15 in Stock
Best Biotech Stocks To Consider - November 18th
Moderna (NASDAQ:MRNA) Stock Falls 3.6% - What's Next?
Top Biotech Stocks To Consider - November 16th
Moderna, Inc. (MRNA) - What Are Analysts Saying About This Stock?
Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow
Promising Biotech Stocks To Consider - November 13th
Brookline Capital Markets Forecasts Moderna FY2026 Earnings
The Next Chapter of mRNA
Moderna (NASDAQ:MRNA) Stock Falls 7% - Here's Why
Promising Biotech Stocks To Watch Today - November 12th
Why Moderna Stock Dropped on Thursday
Moderna Outlines Next Phase of Growth at Analyst Day
FY2029 EPS Forecast for Moderna Decreased by Analyst
Biotech Stocks To Research - November 11th
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom (MRNA)
AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology...

Moderna Media Mentions By Week

Moderna Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MRNA
News Sentiment
▼
0.26

0.39
▲
Average
Healthcare
News Sentiment

Moderna News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MRNA Articles
This Week
▼
37

9
▲
MRNA Articles
Average Week

Moderna Trends on MarketBeat

This week vs. last week
New Followers
4
+33%
Searches
7
-70%
Page Views
6,423
+6%
Get Moderna News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Moderna dated 11/20/2026.
From Our Partners